Avalglucosidase alfa-ngpt_(Nexviazyme®)

Nexviazyme (avalglucosidase alfa‑ngpt) is covered only for the FDA‑approved indication of late‑onset Pompe disease in patients aged ≥1 year and is not covered for other conditions. Coverage requires diagnostic confirmation by deficient acid α‑glucosidase activity (blood, fibroblasts, or muscle) or molecular genetic testing, prescription by or consultation with a geneticist/neurologist/metabolic disorder or lysosomal storage disorder specialist, documentation of age/tests, approval for up to 12 months, and dosing limited to 40 mg/kg IV no more frequently than every 2 weeks.

"Treatment of individuals with late-onset Pompe disease (lysosomal acid α-glucosidase deficiency) — FDA-approved indication"

Sign up to see full coverage criteria, indications, and limitations.